The Shockwave of Marty Makary's Departure

In a move that sent ripples through the medical, pharmaceutical, and political worlds, Dr. Marty Makary, the Commissioner of the U.S. Food and Drug Administration (FDA), resigned abruptly on May 14, 2026. His 13-month tenure, which began after Senate confirmation in early 2025, was defined by bold reforms, intense controversies, and a leadership style that polarized stakeholders. Makary, a renowned surgeon and health policy expert from Johns Hopkins University, stepped down amid mounting pressures from the Trump administration, industry leaders, and patient advocates. The timing of his exit coincided with heightened scrutiny over the FDA's rejection of a promising melanoma treatment, amplifying questions about the agency's decision-making processes.

Makary's resignation was confirmed by President Donald Trump during a press interaction, with Kyle Diamantas, the FDA's deputy commissioner for food policy, stepping in as acting commissioner. This leadership vacuum comes at a critical juncture for public health regulation, as the FDA oversees everything from food safety to groundbreaking drug approvals, impacting 20% of U.S. consumer spending annually.

Understanding Melanoma: A Growing Threat

Melanoma, a type of skin cancer originating in melanocytes—the cells responsible for skin pigmentation—is one of the most aggressive forms of cancer. In 2026, the American Cancer Society projects approximately 112,000 new cases of invasive melanoma in the United States, with around 234,680 total cases including in situ diagnoses. Tragically, about 8,500 Americans are expected to succumb to the disease this year, underscoring its lethality when it metastasizes.

Advanced melanoma, particularly after progression on initial therapies, has a grim five-year survival rate of roughly 16%. Current standard treatments include immunotherapies like nivolumab (brand name Opdivo), a checkpoint inhibitor that unleashes the immune system against tumors. However, many patients develop resistance, leaving a desperate need for next-generation options. This unmet need brought Replimune's RP1 (vusolimogene oderparepvec) into the spotlight.

RP1: The Oncolytic Virus at the Center of the Storm

RP1 represents a novel class of oncolytic immunotherapies—engineered viruses designed to selectively infect and lyse (burst) cancer cells while stimulating a broader immune response. Developed by Massachusetts-based biotech firm Replimune Group, RP1 is a modified herpes simplex virus injected directly into tumors. It not only destroys targeted cells but also expresses proteins like GM-CSF (granulocyte-macrophage colony-stimulating factor) to attract immune cells, potentially reviving exhausted responses from drugs like nivolumab.

The drug received FDA breakthrough therapy designation in November 2024, signaling its potential to substantially improve outcomes over existing therapies. Replimune advanced RP1 through the IGNYTE clinical trial program, culminating in a Biologics License Application (BLA) submission.

The IGNYTE Trial: Promising Data Meets Regulatory Hurdles

The pivotal IGNYTE trial (phase 1/2/3) enrolled 140 patients with anti-PD-1 refractory advanced melanoma—those whose cancers progressed despite nivolumab or similar checkpoint inhibitors. In this single-arm study, patients received RP1 combined with nivolumab. Results were compelling: an objective response rate (ORR) of 33.6%, including 15% complete responses (CR), where tumors vanished entirely. Median duration of response exceeded 24 months for many, with a favorable safety profile—no new toxicity signals beyond manageable flu-like symptoms.

These outcomes dwarfed historical benchmarks, where post-PD-1 response rates hover at 6-7%. Trial leader Dr. Yana Najjar noted patients achieving durable remissions, some with no evidence of disease years later. Yet, the absence of a randomized control arm—deemed unethical given patients' dire prognoses—became the crux of debate.

FDA's Repeated Rejections: Citing Insufficient Evidence

The FDA issued its first Complete Response Letter (CRL) in July 2025, questioning if RP1's benefits were attributable solely to the virus or synergistic with nivolumab. Replimune resubmitted in October 2025 with additional phase 3 IGNYTE-3 data, but a second CRL arrived on April 10, 2026. The agency highlighted a heterogeneous patient population (varying prior treatments, disease burdens), inadequate demonstration of RP1's specific contribution, and trial design flaws.

In the FDA's CRL, reviewers emphasized the need for randomized data to isolate RP1's effect, despite earlier meetings where such designs were discussed as infeasible. For context, other melanoma drugs like Keytruda were approved over a decade ago on single-arm trials, setting precedents RP1 arguably met.

Photo by Taylor Burnfield on Unsplash

Allegations of Confusion and Mixed Signals

Replimune's leadership, including CEO Sushil Patel, accused the FDA of "shifting goalposts." Pre-submission interactions reportedly greenlit the single-arm approach, only for new concerns to emerge. The second review featured a revamped team for "objectivity," fueling perceptions of inconsistency. Makary, in a May 5 CNBC interview, defended the decision vehemently, labeling company critiques as "corporate spin" and insisting, "I don't work for Replimune. I work for the American people."

Oncologist Vinay Prasad, briefly FDA's chief medical officer, played a key role in the rejection before resigning May 1. Critics like regulatory consultant Steven Grossman decried eroded trust: "Uncertainty is bad for everybody—patients, sponsors, investors."

Patient and Expert Backlash

Patient advocates and over 22 oncologists, including Michael Postow, penned an open letter decrying the rejection as a setback for second-line therapies. Dermatologist Trisha Wise-Draper called it "devastating," citing trial patients now cancer-free. Eric Whitman, oncology director, warned of a "chilling effect" on innovation, potentially dooming 2,500 lives annually if RP1 proved viable.

The Wall Street Journal editorialized against the FDA's rigidity, arguing accelerated approval—allowing provisional market access pending confirmatory trials—was warranted. HHS Secretary Robert F. Kennedy Jr. distanced himself, clarifying the decision was FDA's alone.

Economic Repercussions for Replimune

The rejections triggered catastrophe for Replimune: shares plummeted, prompting two layoff rounds slashing over 60% of staff. Manufacturing and marketing halted, threatening operations. Yet, post-Makary resignation, stock surged 30%, with analysts betting on resubmission under new leadership. Replimune persists with RP2, an enhanced candidate in uveal melanoma trials.

Makary's Broader Tenure: Reforms and Rifts

Makary's agenda included AI integration, single pivotal trial approvals for speed, ending animal testing, and ultra-rare disease frameworks. However, 4,000 staff firings bred chaos, with five Center for Drug Evaluation and Research directors in a year. Other flashpoints: rejecting Moderna's flu vaccine, approving leucovorin for rare conditions, and clashes over vaping flavors (resisted youth-appealing options) and mifepristone generics (angered pro-life groups).

Political Underpinnings and Trump Administration Tensions

Makary's ouster stemmed partly from White House frustrations: reluctance on flavored vapes for smoking cessation and perceived foot-dragging on abortion pill reviews. Pro-life activists and pharma CEOs lobbied against him. Amid Trump 2.0's "Make America Healthy Again," the FDA navigated RFK Jr.'s HHS oversight, balancing deregulation with safety.

Photo by HAYOUNG CHO on Unsplash

Looking Ahead: RP1's Path and FDA's Future

Acting Commissioner Diamantas faces immediate tests: will RP1 get revisited? Analysts predict softer stances on single-arm oncology data, especially post-Ebvallo precedent. For patients, hope lingers—IGNYTE-3 confirmatory trial advances. Broader reforms may stabilize, but rebuilding trust demands transparent, science-driven processes.

• Potential accelerated approval under new review.
• Industry push for clearer guidance on trial designs.
• Patient access programs to bridge gaps.

The saga underscores tensions between innovation speed and evidentiary rigor, shaping cancer care's trajectory.